Publications by authors named "S Iyama"
HM-SCREEN-Japan is a multicenter collaborative project in Japan to evaluate the clinical utility of a cancer genome panel in the treatment of acute myeloid leukemia (AML). The HM-SCREEN-JAPAN02 study used the Amoy Myeloid Panel with the HANDLE system, which enables efficient and rapid sequencing, as the genomic testing kit. The Amoy Myeloid Panel targets 53 genes with established clinical significance or high prevalence.
View Article and Find Full Text PDFAcute myeloid leukemia (AML) is an aggressive hematological malignancy with genetic alterations. The FMS-like tyrosine kinase 3 (FLT3) gene is frequently mutated in adult de novo AML, with two types of mutations: internal tandem duplication (ITD) and point mutations in the tyrosine kinase domain. This study aimed to investigate the impact of FLT3 inhibitors and hematopoietic cell transplantation (HCT) on survival outcomes in patients with FLT3-ITD AML in a real-world setting.
View Article and Find Full Text PDFArticle Synopsis
- * Seven patients received autologous MSCs without any serious side effects, showing no tumors or neurological decline throughout the process.
- * Notable functional improvements and enhanced quality of life were reported 90 and 180 days after the infusion, indicating that this treatment could be beneficial for chronic SCI, though further large-scale studies are required for conclusive results.
Introduction: To diagnose sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD), transabdominal ultrasonography is usually used to detect hemodynamic changes, but we tried to detect the changes using four-dimensional computed tomography (4D-CT). A 42-year-old Japanese woman was diagnosed with late-onset SOS/VOD with transabdominal ultrasonography and was also assessed using 4D-CT. Method We analyzed the portal vein (PV) contrast effect every 1.
View Article and Find Full Text PDFArticle Synopsis
- F-FDG PET/CT is commonly used to monitor non-small cell lung cancer (NSCLC), but its impact on the effectiveness of osimertinib treatment for patients with EGFR mutations is not well understood.
- A study of 74 patients found that those with a higher maximum standardized uptake value (SUVmax) in their primary tumors had shorter progression-free survival (PFS) compared to those with lower SUVmax, although overall survival (OS) remained similar.
- High SUVmax was identified as an independent negative predictor for PFS in patients receiving osimertinib, indicating its potential as a useful marker for treatment outcomes.